Follow-up | Variable | Readmission | Mortality | ||||
---|---|---|---|---|---|---|---|
Analysis | Eosinophils | Events (%)‡ | OR (95% CI) | P-value | Events (%)‡ | OR (95% CI) | P-value |
30 days | Continuous | 0.98 (0.9–1.1) | 0.64 | 0.77 (0.5–1.1) | 0.137 | ||
Adjusted | Low | 87 (19.2%) | 1 | 14 (3.1%) | 1 | ||
Medium | 45 (19.0%) | 0.99 (0.7–1.5) | 0.94 | 1 (0.4%) | 0.26 (0.03–2.1) | 0.21 | |
High | 47 (14.1%) | 0.75 (0.5–1.1) | 0.16 | 3 (0.9%) | 0.73 (0.2–2.9) | 0.65 | |
Total events§ | 179 (40.6%) | 18 (33.3%) | |||||
90 days | Continuous | 0.95 (0.9–1.0) | 0.21 | 0.79 (0.6–1.0) | 0.035 | ||
Adjusted | Low | 129 (28.5%) | 1 | 26 (5.8%) | 1 | ||
Medium | 75 (31.6%) | 1.15 (0.8–1.6) | 0.43 | 5 (2.1%) | 0.48 (0.2–1.5) | 0.21 | |
High | 68 (20.4%) | 0.66 (0.5–0.9) | 0.019 | 4 (1.2%) | 0.41 (0.1–1.3) | 0.12 | |
Total events§ | 272 (61.7%) | 35 (64.8%) | |||||
365 days† | Continuous | 0.94 (0.9–1.0) | 0.11 | 0.70 (0.6–0.9) | 0.001 | ||
Adjusted | Low | 207 (45.8%) | 1 | 41 (9.1%) | 1 | ||
Medium | 113 (47.7%) | 0.99 (0.7–1.4) | 0.94 | 8 (3.4%) | 0.42 (0.2–1.0) | 0.061 | |
High | 121 (36.2%) | 0.64 (0.5–0.9) | 0.0051 | 5 (1.5%) | 0.25 (0.09–0.7) | 0.008 | |
Total events§ | 441 (100%) | 54 (100%) |